Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Stummvoll, GH; Aringer, M; Smolen, JS; Schmaldienst, S; Jiménez-Boj, E; Hörl, WH; Graninger, WB; Derfler, K.
IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study.
ANN RHEUM DIS. 2005; 64(7): 1015-1021.
Doi: 10.1136/ard.2004.029660
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Co-authors Med Uni Graz
- Graninger Winfried
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- OBJECTIVE: To analyse the effects of rigorous immunoglobulin removal by immunoadsorption (IAS) on proteinuria (primary outcome variable), disease activity (SIS, SLEDAI, ECLAM), and autoantibodies to double stranded DNA (anti-dsDNA) in active systemic lupus erythematosus (SLE). METHODS: 16 patients with severe SLE and renal disease, in whom cyclophosphamide was contraindicated or failed to halt disease progression, were treated with IAS for 3 months. Patients achieving at least 20% improvement in two or more of the outcome measures were considered responders and offered a 9 months' extension period. RESULTS: Within 3 months, 14 patients responded and 11 opted for an extension. Proteinuria decreased from 6.7 (4.6) g/day (mean (SD)) at baseline to 4.3 (3.5) g/day at 3 months and 2.9 (2.4) g/day at 12 months (p<0.001). From baseline to 3 and 12 months, disease activity improved independently of scoring by SIS (15 (5) to 5 (2) and to 5 (2), p<0.0001), SLEDAI (21 (7) to 5 (4) and to 5 (4), p<0.0001), or ECLAM (7 (2) to 2 (1) and to 3 (1), p<0.0001). Anti-dsDNA fell from 391 (647) IU/ml to 146 (218) and to 53 (50) IU/ml at 3 and 12 months, respectively. Steroids could be tapered from 117 (159) mg/day at baseline to 29 (17) mg/day at 3 months and 9 (2) mg/day at 12 months. IAS was not associated with an excess of infections. However, one patient died of septicaemia after 1 month of treatment. CONCLUSION: In this negatively selected cohort of patients with SLE, IAS was associated with a significant response shown by reduced proteinuria, improved global disease activity, decreased anti-dsDNA, and lower glucocorticoid dosages, suggesting therapeutic benefit.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Analysis of Variance -
- Azathioprine - therapeutic use
- Combined Modality Therapy -
- Female -
- Follow-Up Studies -
- Humans -
- Immunoglobulin G -
- Immunosorbent Techniques -
- Immunosuppressive Agents - therapeutic use
- Lupus Erythematosus, Systemic - drug therapy Lupus Erythematosus, Systemic - immunology Lupus Erythematosus, Systemic - therapy
- Lupus Nephritis - drug therapy Lupus Nephritis - immunology Lupus Nephritis - therapy
- Male -
- Mycophenolic Acid - analogs and derivatives Mycophenolic Acid - therapeutic use
- Patient Selection -
- Prospective Studies -
- Statistics, Nonparametric -